Bionano Genomics (BNGO) Cash & Current Investments (2017 - 2026)

Bionano Genomics' Cash & Current Investments history runs 10 years deep, the most recent figure standing at $14.4 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 21.12% year-over-year to $14.4 million; the TTM figure through Mar 2026 stood at $14.4 million (down 21.12% YoY), while the FY2025 annual figure was $19.3 million, up 103.37% from the prior year.
• Cash & Current Investments came in at $14.4 million for Q1 2026 at Bionano Genomics, down from $19.3 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $216.4 million in Q1 2022 to a low of $5.1 million in Q4 2022.
• A 5-year average of $61.0 million and a median of $19.8 million in 2024 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments sank 97.97% in 2022 and surged 942.33% in 2023, its largest moves.
• Bionano Genomics' Cash & Current Investments stood at $5.1 million in 2022, then soared by 942.33% to $53.1 million in 2023, then plunged by 82.14% to $9.5 million in 2024, then jumped by 103.37% to $19.3 million in 2025, then slipped by 25.37% to $14.4 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $14.4 million, $19.3 million, and $13.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison